With an analyst consensus upside of 52.3%, CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the under-the-radar stocks with ...

A CRISPR Therapy Just Cured A Disease From Inside The Body For The First Time. The Gene-Editing Era Officially Started Monday.

Researchers at Cornell University have developed a safer and more precise way to study how genes function in living tissues ...

Are there significant gains ahead for one (or both) of these innovative biotechs?

Learn how CRISPR ETFs provide access to the gene-editing revolution, offering investors a diversified approach without picking individual biotech stocks.

Intellia Therapeutics said its Crispr-based treatment for hereditary angioedema met its goals in a Phase 3 trial, marking a milestone for gene editing.

The biotech's candidate may treat a great number of illnesses that have one thing in common.

CRISPR Therapeutics (NasdaqGM:CRSP) is entering a second phase of its business as the CASGEVY commercial rollout gains momentum. The company reports new patient initiations for CASGEVY alongside ...

If the first CRISPR decade was marked by a mad dash to evolve, engineer, and mine the bacterial universe for more and better genome-editing enzymes, so far the second seems to be all about three words ...

CRISPR-based genome editing has transformed biological research. Since the advent of the technology in 2012, Addgene has ...

Researchers developed ΨDNA, a DNA-based CRISPR guide that allows Cas12 enzymes to target RNA with high specificity while ...

Researchers at the Ruhr University Bochum have developed a novel antiviral concept: Using the CRISPR/Cas13 system, they were ...